Comparative Pharmacology
Head-to-head clinical analysis: BUTALAN versus SODIUM BUTABARBITAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BUTALAN versus SODIUM BUTABARBITAL.
BUTALAN vs SODIUM BUTABARBITAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Butalan is an ergot alkaloid derivative that acts as a partial agonist at serotonin (5-HT2B) receptors and an antagonist at alpha-adrenergic and dopamine (D2) receptors. It also inhibits prolactin secretion by stimulating dopamine receptors in the pituitary.
Barbiturate that enhances GABA-A receptor activity, increasing chloride ion conductance and causing CNS depression.
1-2 tablets (50-100 mg butalbital, 325-650 mg acetaminophen, 40 mg caffeine) orally every 4 hours as needed, not exceeding 6 tablets per day.
50-100 mg orally or intramuscularly 3-4 times daily as a sedative; 100-200 mg orally or intramuscularly for preoperative sedation.
None Documented
None Documented
4-6 hours (terminal); prolonged in renal impairment (up to 12-15 hours)
Terminal elimination half-life 40-60 hours in adults; prolonged in hepatic impairment and elderly.
Primarily renal (70% unchanged, 20% as metabolites); fecal 10%
Renal excretion of unchanged drug and metabolites; approximately 30-50% as unchanged drug in urine. Minor fecal elimination (<5%).
Category C
Category C
Barbiturate
Barbiturate